The New England Journal of Medicine recently published results from a series of clinical trials testing the effects of new glucose-lowering medications in type 2 diabetes. While the primary outcomes of these trials were cardiovascular events, several clinical trials also presented effects on diabetic kidney disease. In an editorial, Dr. de Boer comments on the beneficial kidney effects observed for SGLT2 inhibitors and GLP1 receptor agonists, and how these effects may ultimately impact the course of kidney disease for patients with type 2 diabetes.

New England Journal of Medicine